There are no FDA-approved, self-administered, pharmaceutical treatment options to stop PSVT or atrial fibrillation, and limited to no options for patients experiencing acute anginal symptoms. Milestone’s lead investigational candidate, etripamil, aims to address a significant unmet medical need for self-administered products to terminate these episodes in the outpatient setting.

Etripamil is a proprietary, small molecule, new chemical entity that was conceived, discovered, and optimized by Milestone. Etripamil is currently being tested in Phase 3 trials for PSVT. It is administered intranasally to allow for rapid systemic drug delivery. Etripamil is designed to be fast-acting with a short half-life, measured in minutes. Etripamil is not currently approved for the treatment of PSVT or for any other indication anywhere in the world.